A Study of ABT-263 as Single Agent in Women With Platinum Resistant/Refractory Recurrent Ovarian Cancer

Inclusion Criteria: * \- Woman older than 18 years * Subjects with Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 * Histologically and/or cytologically documented high grade serous epithelial cancer of ovarian, fallopian tube or peritoneum * Platinum resistant ovarian cancer defined as relapsing within 6 months after a platinum based chemotherapy OR platinum refractory ovarian cancer defined as progressing during a platinum based chemotherapy (excepted refractory patients in first line) * Subjects having received at least 2 prior lines of treatments including platinum regimen * Subjects who are willing and able to comply with the protocol and study procedures including willingness to undergo tumor biopsy before therapy at screening * There is no limitation to prior number of therapies * Patients must have documented disease progression * Subjects who have measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 * Adequate bone marrow, renal and hepatic function per local laboratory reference range as follows:• Absolute Neutrophil Count ≥ 1500/ mm3 * Platelets ≥ 150,000 / mm3 * Hemoglobin ≥ 9.0 g/dL * Renal function: Serum creatinine ≤1.2mg/dL or calculated creatinine clearance ≥ 60mL/min * AST/ALT ≤ 3.0× the upper limit of normal (ULN); \[Subjects with liver metastasis may have AST, ALP, and ALT less then or equal to 5.0 X ULN\] * Bilirubin ≤ 1.25×ULN * Coagulation: aPTT and PT not to exceed 1.2 × ULN * LVEF \> 50% by echocardiograms or MUGA * Patients must give written informed consent Exclusion Criteria: * Patient's refusal or impossibility to perform biopsy on relapsing disease * Bowel occlusive syndrome or other gastro-intestinal disorder that does not allow oral medication such as malabsorption * Patients with platinum refractory disease in first line * Received radio-immunotherapy within 6 months of 1st dose of study drug * Received steroid therapy for anti-neoplastic intent within 7 days of the 1st dose of study drug (Inhaled steroids for asthma, topical steroids, replacement/stress corticosteroids, or corticosteroids taken as premedication are allowed) * Consumption of grapefruit or grapefruit products within 3 days prior to the first dose of study drug * Patient receiving treatments strong CYP3A4 inhibitors or inducers (Appendix A) * Positive for HIV and VHC * Predisposing condition/currently exhibiting signs of bleeding * Currently receiving anticoagulation therapy, exception of low-dose anticoagulation medications for prophylaxis * Received aspirin within 7 days of start dose of study drug * Active peptic ulcer disease / other potentially hemorrhagic esophagitis/gastritis * Active immune thrombocytopenic purpura, autoimmune hemolytic anemia or history of being refractory to platelet transfusions (within 1 year of 1st dose of study drug) * Uncontrolled cardiac, renal, neurologic, psychiatric, endocrinologic, metabolic, immunologic, or hepatic disease, active systemic fungal infection; diagnosis of fever and neutropenia within 1 week of study drug administration * A evidence of current/active malignancies other than ovarian cancer * Pregnant or lactating women